A team of researchers at the University of Michigan has found a supplement containing stem-derived stem cells could help people with Alzheimer.
The supplement, called NicalisStem, is manufactured by a company called Meditropins and is intended to help improve cognition in people with dementia.
NicaliStem has been used for decades in people who have suffered from Alzheimer’s, but only recently has it begun to show promise in people.
It works by mimicking the immune system of Alzheimer’s patients to help them stay alert and healthy, while also reducing inflammation and oxidative stress, said Dr. Eric G. Wieden, a neuroscientist and a member of the U-M team.
Nicals stem cells, or stem cells made from a person’s own cells, have long been touted as a treatment for Alzheimer’s.
They have been shown to help slow or stop memory loss in people, help fight cancer and other diseases, and reduce inflammation and swelling in the brain.
But researchers have not been able to find a way to use stem cells in clinical trials.
“It’s a lot of work, but we’re beginning to get some encouraging results,” said Dr., who was not involved in the new study.
“The best thing we can do is find a clinical trial that shows promise and can do some tests in humans.”
Meditaprin, a derivative of Nicalias stem cells called Nicals, has been approved by the Food and Drug Administration as a prescription drug.
Meditapein is also a registered drug for treating severe allergic reactions, and is a supplement used by many cancer patients.
But the company did not have a clinical study underway to prove it could be used for Alzheimer patients.
To do that, the researchers have been working with other scientists to find studies that use Nicalitins stem cells for clinical trials in people and to identify the effects of Nicals on brain activity.
“I think that if we can replicate the results, we should be able to demonstrate efficacy,” said Professor Wiede, who was part of the team that created the supplement.
“We’re in the early stages, but it looks like we’re on the right track.”
The supplement is available through a pharmacy, and NicalinStem is expected to be on the market in 2018.
NialisStems is the second of Niales supplements to be approved by FDA, after Meditrax, which was approved by Health Canada in 2015.
Both supplements contain stem cells derived from human cells, and Meditrapins claims it can use stem cell technology to develop therapies to treat Alzheimer’s and other disorders.
The FDA approved MeditraX, a supplement made from stem cells from humans.
The agency has also approved Nicaliscene, a product that uses stem cells and is based on Nicalistin, the Nicalisi stem cell product.
Dr. Wiesen said Nicalists stem cells are similar to the ones in a patient’s own blood, and that it is not clear if Nicalisa stem cells can be used to treat other diseases.
“If we can find a cell therapy that can be effective in people or can work for people, we could potentially have a real breakthrough in treating this disease,” said Niali, who is also the director of the Institute for Brain Sciences and is affiliated with the University.
“This is a very exciting discovery.”
The U-Men researchers also found that the Nicals product, Nicalislix, has similar activity to Nicalispin, a stem cell supplement used in humans.
“While Nicalicis is not a safe compound, it may be more effective than Nicalimax,” said study author Dr. James B. Rieder, a professor in the U’M Department of Pharmacology.
Nies stem cells also have a protective effect against inflammation and are protective against oxidative stress.
In humans, the compound also showed a protective role against oxidative damage in the blood, he said.
The research was published online April 14 in the journal Cell Reports.
For more information, contact Dr. Nancy D. Bialystock at 202-662-8255.